CervoMed to Participate in the Emerging Growth Conference
July 17, 2024 08:00 ET
|
CervoMed Inc.
BOSTON, July 17, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company’s...
CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024
July 11, 2024 08:51 ET
|
CervoMed Inc.
Phase 2b RewinD-LB trial of neflamapimod for the treatment of dementia with Lewy bodies is fully enrolled with topline data expected in December 2024 BOSTON, July 11, 2024 (GLOBE NEWSWIRE) --...
CervoMed Announces Addition to Russell 2000® and Russell 3000® Indexes
June 24, 2024 08:00 ET
|
CervoMed Inc.
BOSTON, June 24, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced its expected...
CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies
June 11, 2024 08:00 ET
|
CervoMed Inc.
- Topline data expected in December 2024 - - Phase 2b design optimized for success; clear path to market in this high value indication expected with positive result - BOSTON, June 11, 2024 (GLOBE...
CervoMed to Appoint William Elder as Chief Financial Officer
May 20, 2024 08:00 ET
|
CervoMed Inc.
BOSTON, May 20, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced the appointment...
CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates
May 15, 2024 08:00 ET
|
CervoMed Inc.
- CervoMed on track to complete enrollment in 2Q 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies (DLB); topline data expected in 4Q...
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
April 01, 2024 08:00 ET
|
CervoMed Inc.
- Announced private placement of up to $149.4 million led by RA Capital Management with participation from Armistice Capital, Special Situations Funds and Soleus Capital; pro forma cash and cash...
CervoMed to Participate in Upcoming Investor Conferences
March 28, 2024 16:05 ET
|
CervoMed Inc.
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that...
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors
March 28, 2024 08:30 ET
|
CervoMed Inc.
Funding from new investors, including RA Capital Management, Armistice Capital, Special Situations Funds and Soleus Capital $50 million financing upfront with up to an additional $99.4 million tied...
CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024
March 05, 2024 08:00 ET
|
CervoMed Inc.
- Neflamapimod led to significant reduction compared to placebo in plasma levels of glial fibrillary acidic protein (GFAP) - Neflamapimod effects on GFAP correlated to clinical outcomes assessed by...